Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 7/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.59 |
| ▸ | ALPI | P09923 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | XIAP | P98170 | 1/20 | 0.59 |
| ▸ | NOS3 | P29474 | 3/20 | 0.58 |
| ▸ | NOS1 | P29475 | 3/20 | 0.58 |
| ▸ | NOS2 | P35228 | 3/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.57 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.57 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.57 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.56 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL202409 | 1.00 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL31538733 | 1.00 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL202408 | 1.00 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL18049406 | 0.94 | SLC7A5 (0.59) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL7371250 | 0.90 | SLC7A5 (0.60) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL667717 | 0.87 | SLC7A5 (0.68) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL29637609 | 0.87 | SLC7A5 (0.68) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL21690081 | 0.87 | SLC7A5 (0.68) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL30834634 | 0.87 | SLC7A5 (0.68) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL667716 | 0.87 | SLC7A5 (0.68) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4401555-A1 | ANTIMICROBIAL PEPTIDES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2024-07-24 | — | — | EP | claimed |
| US-20240081329-A1 | NON-PROTEIN PHENYLALANINE ANALOGUES FOR INHIBITING CYANOBACTERIA AND PLANT GROWTH | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-03-14 | — | — | US | claimed |
| WO-2023042201-A1 | ANTIMICROBIAL PEPTIDES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-03-23 | — | — | WO | claimed |
| EP-2951195-B1 | ANTIFOULING MATERIALS | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2020-02-19 | — | — | EP | claimed |
| US-20190246638-A1 | NON-PROTEIN PHENYLALANINE ANALOGUES FOR INHIBITING CYANOBACTERIA AND PLANT GROWTH | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2019-08-15 | — | — | US | claimed |
| EP-3416488-A1 | NON-PROTEIN PHENYLALANINE ANALOGUES FOR INHIBITING CYANOBACTERIA AND PLANT GROWTH | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2018-12-26 | — | — | EP | claimed |
| EP-3374520-A1 | BIOSENSORS | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2018-09-19 | — | — | EP | claimed |
| WO-2017141253-A1 | NON-PROTEIN PHENYLALANINE ANALOGUES FOR INHIBITING CYANOBACTERIA AND PLANT GROWTH | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2017-08-24 | — | — | WO | claimed |
| US-9695191-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2017-07-04 | — | — | US | claimed |
| WO-2017081684-A1 | BIOSENSORS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2017-05-18 | — | — | WO | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| WO-2014118779-A1 | ANTIFOULING MATERIALS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-08-07 | — | — | WO | claimed |
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-08-09 | — | — | US | claimed |
| US-20110312873-A1 | N-TERMINALLY MODIFIED TETRAPEPTIDE DERIVATIVES HAVING A C-TERMINAL ARGININE MIMETIC | PHILIPPS-UNIVERSITAT MARBURG (DE) | 2011-12-22 | — | — | US | claimed |
| EP-2349312-A2 | N-TERMINALLY MODIFIED TETRAPEPTIDE DERIVATIVES HAVING A C-TERMINAL ARGININE MIMETIC | Philipps-Universität Marburg (DE) | 2011-08-03 | — | — | EP | claimed |
| WO-2010048941-A2 | N-TERMINALLY MODIFIED TETRAPEPTIDE DERIVATIVES HAVING A C-TERMINAL ARGININE MIMETIC | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2010-05-06 | — | — | WO | claimed |
| EP-1483285-B1 | INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME | CURACYTE AG (DE) | 2008-05-07 | — | — | EP | claimed |
| US-20050119190-A1 | Inhibitors of the blood-clotting factor xa, production thereof and use of the same | CURACYTE AG (DE) | 2005-06-02 | — | — | US | claimed |
| EP-1483285-A1 | INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME | Curacyte AG (DE) | 2004-12-08 | — | — | EP | claimed |
| WO-2003076457-A1 | INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME | CURACYTE AG (DE) | 2003-09-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202821-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | HTR2B, MC1R, HTR1A | SLC7A5 1600/4885PTGS1 109/4885ALPI 2014/4885 |
| US-20190246638-A1 | NON-PROTEIN PHENYLALANINE ANALOGUES FOR INHIBITING CYANOBACTERIA AND PLANT GROWTH | GLUL, PAH, PLPBP | SLC7A5 245/4885PTGS1 1359/4885ALPI 3987/4885 |
| US-20050119190-A1 | Inhibitors of the blood-clotting factor xa, production thereof and use of the same | SERPINC1, TFPI, F11 | SLC7A5 4712/4885PTGS1 1407/4885ALPI 2075/4885 |
| US-20110312873-A1 | N-TERMINALLY MODIFIED TETRAPEPTIDE DERIVATIVES HAVING A C-TERMINAL ARGININE MIMETIC | FURIN, IAPP, APP | SLC7A5 2233/4885PTGS1 3773/4885ALPI 3589/4885 |
| US-20240081329-A1 | NON-PROTEIN PHENYLALANINE ANALOGUES FOR INHIBITING CYANOBACTERIA AND PLANT GROWTH | GLUL, PAH, PLPBP | SLC7A5 245/4885PTGS1 1359/4885ALPI 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.